Elan moves to deter takeover bid
(AP)—Irish drug maker Elan Corp. announced Monday it will pay shareholders a recurring special dividend linked to the sales of the multiple sclerosis treatment Tysabri.
Mar 4, 2013
0
0
(AP)—Irish drug maker Elan Corp. announced Monday it will pay shareholders a recurring special dividend linked to the sales of the multiple sclerosis treatment Tysabri.
Mar 4, 2013
0
0
British drugmaker GlaxoSmithKline on Wednesday said it had gone hostile over its $2.6 billion (2.0 billion-euro) takeover bid for US research partner Human Genome Sciences Inc.
May 9, 2012
0
0
Swiss pharmaceutical group Roche said Tuesday the US Federal Trade Commission had requested additional information on its hostile $5.7-billion (4.2 billion euros) bid for US gene mapper Illumina.
Mar 13, 2012
0
0
Swiss pharmaceutical group Roche said Monday it is sticking by its hostile $5.7-billion (4.2 billion euros) bid for US gene mapper Illumina and is extending it for a month.
Feb 27, 2012
0
0